Monjaro vs Zepbound: Identical Tirzepatide, Different FDA Indications, and Why That Matters for Your Prescription

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Monjaro and Zepbound contain the exact same active ingredient (tirzepatide) at identical doses (2.5 mg through 15 mg), manufactured by the same company (Eli Lilly)
• The only regulatory difference is FDA indication: Monjaro for type 2 diabetes (approved May 2022), Zepbound for chronic weight management (approved November 2023)
• Insurance coverage differs dramatically based on diagnosis code, not drug composition, with most plans covering Monjaro for diabetes but requiring prior authorization or denying Zepbound for obesity
• Patients without diabetes who meet weight-management criteria can access tirzepatide through Zepbound, compounded tirzepatide from 503B pharmacies, or off-label Monjaro prescribing (though the last option faces increasing payer resistance)

Direct answer (40-60 words)

Monjaro and Zepbound are the same molecule (tirzepatide) at the same doses, made by the same manufacturer. Monjaro received FDA approval for type 2 diabetes in May 2022. Zepbound received separate FDA approval for chronic weight management in November 2023. The clinical difference is the diagnosis code on your prescription, which determines insurance coverage.

Table of contents

1. The regulatory split: why Eli Lilly filed two separate applications
2. Head-to-head comparison: formulation, dosing, and administration
3. The clinical trial programs behind each approval
4. Insurance coverage logic and the diagnosis code problem
5. What most articles get wrong about "same drug, different purpose"
6. When a provider can prescribe Monjaro for weight loss (and when they can't)
7. Compounded tirzepatide as the third option
8. Cost comparison: list price, coupon programs, and out-of-pocket reality
9. The decision tree: which version you should ask for
10. Side effect profiles: do they differ?
11. FAQ
12. Sources

The regulatory split: why Eli Lilly filed two separate applications

Eli Lilly developed tirzepatide as a dual GIP/GLP-1 receptor agonist starting in 2014. The molecule activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors, which made it a candidate for both diabetes control and weight management from the beginning.

The company chose to pursue two separate FDA approval pathways rather than a single approval with multiple indications. This is a strategic regulatory decision, not a scientific one. The FDA evaluates drugs based on the clinical trial evidence submitted for a specific indication. Filing separately allowed Eli Lilly to:

1. Bring Monjaro to market faster for diabetes patients. The SURPASS trial program (diabetes-focused) finished enrollment earlier than the SURMOUNT program (obesity-focused). Waiting to file both indications together would have delayed diabetes patient access by 18 months.

1. Price and position the products differently. Diabetes medications and obesity medications face different payer scrutiny, different prior authorization requirements, and different patient cost-sharing structures. Separate brand names allow separate pricing strategies.

1. Market to different prescriber audiences. Endocrinologists prescribe diabetes drugs. Bariatric specialists, primary care physicians managing obesity, and increasingly telehealth weight-management platforms prescribe obesity drugs. Separate brands allow targeted marketing and education to each group.

The result is two FDA-approved products with identical active pharmaceutical ingredients but different National Drug Codes (NDCs), different package inserts, and different reimbursement pathways.

From a pharmacology standpoint, the drugs are interchangeable. From a regulatory and insurance standpoint, they are not.

Head-to-head comparison: formulation, dosing, and administration

Feature	Monjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly and Company	Eli Lilly and Company
FDA approval date	May 13, 2022	November 8, 2023
Approved indication	Type 2 diabetes mellitus (adjunct to diet and exercise)	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity
Available doses	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Dosing schedule	Once weekly subcutaneous injection	Once weekly subcutaneous injection
Injection device	Single-dose prefilled pen (KwikPen)	Single-dose prefilled pen (same device as Monjaro)
Starting dose	2.5 mg once weekly for 4 weeks, then escalate	2.5 mg once weekly for 4 weeks, then escalate
Maintenance dose range	5 mg to 15 mg (individualized based on glycemic control)	5 mg to 15 mg (individualized based on weight-loss response and tolerability)
Formulation	Sterile aqueous solution, pH 7.0 to 8.0	Sterile aqueous solution, pH 7.0 to 8.0 (identical formulation)
Excipients	Sodium chloride, sodium phosphate dibasic heptahydrate, water for injection	Sodium chloride, sodium phosphate dibasic heptahydrate, water for injection (identical)
Storage	Refrigerate 36°F to 46°F; may store at room temperature up to 21 days	Refrigerate 36°F to 46°F; may store at room temperature up to 21 days
List price (15 mg dose)	$1,069.08 per month (4 pens)	$1,059.87 per month (4 pens)
Savings card availability	Yes (Monjaro Savings Card, up to $550/month off, eligibility restrictions apply)	Yes (Zepbound Savings Card, up to $550/month off, eligibility restrictions apply)

The formulations are pharmaceutically equivalent. A 10 mg dose of Monjaro delivers the same 10 mg of tirzepatide as a 10 mg dose of Zepbound, with the same pharmacokinetic profile, same half-life (approximately 5 days), and same receptor binding characteristics.

The pen devices are visually identical except for branding. Both use a single-use, prefilled, disposable pen with a hidden needle and an auto-injection mechanism. The patient experience of administering the injection is the same.

The clinical trial programs behind each approval

Monjaro's approval relied on the SURPASS trial program, which enrolled patients with type 2 diabetes. Zepbound's approval relied on the SURMOUNT trial program, which enrolled patients with obesity or overweight with comorbidities, most of whom did not have diabetes.

SURPASS trials (Monjaro, diabetes indication):

• SURPASS-1 (N = 478): Tirzepatide monotherapy vs placebo in treatment-naive type 2 diabetes. A1C reduction of 1.87% to 2.07% depending on dose, vs 0.04% for placebo (Rosenstock et al., Lancet 2021).
• SURPASS-2 (N = 1,879): Tirzepatide vs semaglutide 1 mg in type 2 diabetes on metformin. A1C reduction of 2.01% to 2.46% for tirzepatide vs 1.86% for semaglutide. Weight loss of 7.6 kg to 12.4 kg for tirzepatide vs 5.7 kg for semaglutide (Frías et al., NEJM 2021).
• SURPASS-3 (N = 1,444): Tirzepatide vs insulin degludec, both added to metformin. A1C reduction of 1.93% to 2.37% for tirzepatide vs 1.34% for insulin (Ludvik et al., Lancet 2021).
• SURPASS-4 (N = 2,002): Tirzepatide vs insulin glargine in patients with type 2 diabetes and elevated cardiovascular risk. A1C reduction of 2.11% to 2.46% for tirzepatide vs 1.44% for insulin. Cardiovascular safety confirmed (Del Prato et al., Lancet 2021).
• SURPASS-5 (N = 475): Tirzepatide added to insulin glargine with or without metformin. A1C reduction of 2.11% to 2.40% (Dahl et al., Lancet Diabetes Endocrinol 2022).

Across SURPASS trials, weight loss was a consistent secondary endpoint. Patients on 15 mg tirzepatide lost an average of 11 to 13 kg (24 to 29 pounds) over 40 weeks, even though weight loss was not the primary goal.

SURMOUNT trials (Zepbound, obesity indication):

• SURMOUNT-1 (N = 2,539): Tirzepatide vs placebo in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidity) but without diabetes. Mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs 3.1% for placebo at 72 weeks. Primary endpoint met: significantly more patients achieved ≥5% weight loss (Jastreboff et al., NEJM 2022).
• SURMOUNT-2 (N = 938): Tirzepatide vs placebo in adults with obesity and type 2 diabetes. Mean weight loss of 12.8% (10 mg) and 14.7% (15 mg) vs 3.2% for placebo at 72 weeks (Garvey et al., Lancet 2023).
• SURMOUNT-3 (N = 670): Tirzepatide vs placebo after a 12-week run-in period on tirzepatide. Patients randomized to continue tirzepatide lost an additional 5.5% body weight, while those switched to placebo regained 2.5% (Aronne et al., JAMA 2024).
• SURMOUNT-4 (N = 731): Tirzepatide vs placebo in patients with obesity and obstructive sleep apnea. Weight loss of 18.1% to 20.1% for tirzepatide vs 1.3% for placebo. Apnea-hypopnea index (AHI) improved by 25 to 30 events per hour (Malhotra et al., NEJM 2024).

The SURMOUNT program demonstrated that tirzepatide produces clinically meaningful weight loss in patients without diabetes. The magnitude of weight loss (15% to 21% at 72 weeks) exceeds that seen with semaglutide 2.4 mg (STEP trials showed 12% to 15% weight loss) and positions tirzepatide as the most effective GLP-1-based obesity medication currently available.

The FDA evaluated these two trial programs separately and granted two separate approvals. The molecule is the same. The patient populations and endpoints differed.

Insurance coverage logic and the diagnosis code problem

Here is the part that confuses patients and providers: insurance companies do not cover drugs based on the active ingredient. They cover drugs based on the FDA-approved indication, the diagnosis code (ICD-10) on the prescription, and the specific NDC billed.

For Monjaro (diabetes indication):

• Covered by most commercial insurance plans and Medicare Part D for patients with a diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Typically requires step therapy (patient must try metformin first, sometimes metformin plus a second agent)
• Prior authorization required by most plans but approval rate is high for appropriate diabetes diagnoses
• Copay ranges from $10 to $75 per month for insured patients after deductible

For Zepbound (obesity indication):

• Covered by fewer than 30% of commercial insurance plans as of April 2026
• Medicare Part D explicitly excludes coverage for weight-loss medications under the statutory "lifestyle drug" exclusion (Social Security Act Section 1860D-2)
• Medicaid coverage varies by state; 15 states cover GLP-1s for obesity as of 2026, 35 do not
• Prior authorization required by all plans that cover it, with strict BMI and comorbidity documentation requirements
• Copay ranges from $25 to $500 per month where covered; many plans apply it to specialty tier with coinsurance rather than flat copay

The diagnosis code trap:

A provider cannot prescribe Monjaro and write "obesity" as the diagnosis. The claim will deny. The reverse is also true: prescribing Zepbound with a diabetes diagnosis code creates a coverage mismatch.

Patients with both diabetes and obesity face a choice:

• Use Monjaro, which insurance will cover for diabetes, and benefit from the weight loss as a secondary effect
• Use Zepbound, which insurance likely will not cover even though the patient has obesity, because the diabetes diagnosis makes Monjaro the "appropriate" covered option

Patients with obesity but no diabetes have no covered Monjaro pathway. Their options are Zepbound (if their plan covers it), compounded tirzepatide, or out-of-pocket brand-name medication.

This is not a clinical distinction. It is a billing and reimbursement distinction that creates access barriers unrelated to medical appropriateness.

What most articles get wrong about "same drug, different purpose"

Most comparison articles say "Monjaro is for diabetes, Zepbound is for weight loss" and stop there. That framing is incomplete and misleading in three specific ways.

Error 1: Implying the drugs work differently.

The mechanism of action is identical. Tirzepatide activates GIP and GLP-1 receptors regardless of which branded pen delivers it. The blood glucose reduction you get from Monjaro is the same as the blood glucose reduction you get from Zepbound at the same dose. The weight loss you get from Zepbound is the same as the weight loss you get from Monjaro at the same dose.

The SURPASS-2 trial (diabetes patients on Monjaro) showed 12.4 kg weight loss at 15 mg. The SURMOUNT-1 trial (obesity patients on Zepbound) showed 20.9% body weight reduction, which for a 100 kg patient is 20.9 kg. The difference in absolute kilograms lost is explained by baseline weight and trial duration (40 weeks vs 72 weeks), not drug effect.

Error 2: Suggesting Monjaro is unsafe or inappropriate for weight loss.

Monjaro is widely prescribed off-label for weight management in patients without diabetes. Off-label prescribing is legal and common. The clinical evidence supporting tirzepatide for weight loss exists regardless of brand name. A provider who prescribes Monjaro to a patient with obesity (BMI ≥30) and no diabetes is practicing evidence-based medicine. The insurance company may deny the claim, but the prescribing decision is sound.

The confusion arises because payers increasingly audit and deny off-label Monjaro claims for weight management, especially after Zepbound's approval. The payer logic is: "An FDA-approved option for your indication exists (Zepbound). We will not cover the diabetes-indicated version (Monjaro) for a non-diabetes diagnosis." This is a coverage policy, not a safety or efficacy issue.

Error 3: Ignoring the patient population overlap.

Approximately 85% of adults with type 2 diabetes have overweight or obesity (CDC data, 2023). Most patients prescribed Monjaro for diabetes also have obesity. They are getting both benefits (glucose control and weight loss) from a single medication.

The "different purpose" framing implies two separate patient populations. In reality, the populations overlap substantially. The regulatory split creates artificial boundaries that do not reflect clinical practice.

When a provider can prescribe Monjaro for weight loss (and when they can't)

Legally permissible (off-label prescribing):

A licensed provider can prescribe Monjaro for chronic weight management in a patient without diabetes if:

• The patient meets clinical criteria (BMI ≥30, or BMI ≥27 with weight-related comorbidity)
• The provider documents medical necessity
• The patient is informed that this is off-label use
• The patient consents

Off-label prescribing is a standard part of medical practice. The FDA regulates drug approvals, not the practice of medicine. Providers prescribe FDA-approved drugs for non-approved indications every day across all therapeutic areas.

Practically difficult (payer resistance):

Even though off-label Monjaro prescribing is legal, insurance companies can and do deny coverage. After Zepbound's approval in November 2023, major payers updated their policies:

• UnitedHealthcare (updated January 2024): Monjaro coverage limited to ICD-10 codes E11.x (type 2 diabetes). Claims with obesity codes (E66.x) without concurrent diabetes diagnosis will deny.
• Anthem (updated February 2024): Requires diagnosis of type 2 diabetes for Monjaro. Zepbound requires BMI ≥30 or BMI ≥27 with comorbidity, prior 6-month weight management program, and no diabetes diagnosis.
• Aetna (updated March 2024): Similar split. Monjaro for diabetes only. Zepbound for obesity without diabetes.

The result: a provider can write the prescription, but the patient will pay out of pocket unless they meet the specific diagnosis criteria the payer has set for each brand.

The workaround some providers use:

For patients with both prediabetes (A1C 5.7% to 6.4%) and obesity, some providers prescribe Monjaro using the prediabetes diagnosis code (R73.03). This is technically off-label (Monjaro is approved for type 2 diabetes, not prediabetes), but it sometimes passes payer edits because the diagnosis code is in the diabetes/glucose disorder family.

This is a gray area. It is not fraudulent if the patient truly has prediabetes and the provider documents that tirzepatide is being used to prevent progression to diabetes (a reasonable clinical goal). It becomes problematic if the prediabetes diagnosis is exaggerated or fabricated solely to obtain coverage.

FormBlends does not recommend or support diagnosis code manipulation. We are documenting the practice because patients encounter it and deserve to understand the coverage dynamics at play.

Compounded tirzepatide as the third option

Patients who do not have insurance coverage for either Monjaro or Zepbound can access tirzepatide through FDA-registered 503B outsourcing facilities, which compound the medication in response to individual prescriptions.

Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy using tirzepatide active pharmaceutical ingredient (API) sourced from FDA-registered suppliers. The final product has not undergone the same review process as brand-name Monjaro or Zepbound.

Key differences:

Feature	Brand-name (Monjaro/Zepbound)	Compounded tirzepatide
FDA approval	Yes (separate approvals for each brand)	No (compounded drugs are not FDA-approved)
Manufacturing	Eli Lilly, FDA-inspected facility	503B outsourcing facility, FDA-registered and inspected
Dosing options	2.5, 5, 7.5, 10, 12.5, 15 mg (fixed doses)	Customizable; common doses mirror brand-name, but 1 mg, 3 mg, and other increments possible
Delivery device	Prefilled single-use pen	Typically multi-dose vial requiring patient to draw dose with insulin syringe, or prefilled syringe
Cost	$1,000+ per month list price; $25 to $550 with insurance or savings card	$250 to $450 per month out-of-pocket (no insurance accepted by most compounders)
Insurance coverage	Possible (depends on diagnosis and plan)	No (compounded medications are not covered by insurance)
Availability during shortage	Subject to supply constraints	Legally available during FDA shortage periods; restricted when brand-name supply normalizes

The FDA allows compounding of tirzepatide under specific conditions. As of April 2026, tirzepatide remains on the FDA drug shortage list, which permits 503B facilities to compound it. If Eli Lilly resolves the shortage and the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop producing it (per FDA guidance on compounding drugs that are essentially copies of approved products).

FormBlends connects patients with compounded tirzepatide through a network of licensed providers and FDA-registered 503B pharmacies. All prescribing decisions are made by independent licensed providers based on individual patient evaluation.

Cost comparison: list price, coupon programs, and out-of-pocket reality

List prices (April 2026):

• Monjaro: $1,069.08 per month (four weekly doses)
• Zepbound: $1,059.87 per month (four weekly doses)
• Compounded tirzepatide: $250 to $450 per month depending on dose and pharmacy

Savings card programs:

Eli Lilly offers manufacturer savings cards for both Monjaro and Zepbound. Eligibility and discount amounts are identical:

• Maximum savings: $550 per month
• Eligibility: Commercially insured patients (excludes Medicare, Medicaid, and uninsured patients in some states)
• Effective cost with card: $25 per month if insurance covers the medication
• Duration: Up to 24 months of savings (terms updated periodically)

The savings card does not help if insurance denies the claim entirely. It reduces copay for approved claims only.

Real-world out-of-pocket costs:

Patient scenario	Monjaro cost	Zepbound cost	Compounded tirzepatide cost
Commercially insured, diabetes diagnosis, Monjaro covered	$25 to $75/month with savings card	Not applicable (would not be prescribed)	$250 to $450/month
Commercially insured, obesity without diabetes, Zepbound covered	Not applicable	$25 to $500/month depending on plan tier and savings card eligibility	$250 to $450/month
Commercially insured, obesity without diabetes, Zepbound NOT covered	$1,069/month (denied claim, no savings card benefit)	$1,060/month out-of-pocket, or $510/month with savings card if paying cash	$250 to $450/month
Medicare Part D, diabetes diagnosis	$35 to $150/month (Part D covers Monjaro for diabetes)	Not applicable (Part D excludes weight-loss drugs)	$250 to $450/month
Medicare Part D, obesity without diabetes	Not applicable (off-label denial likely)	$1,060/month (no Part D coverage, savings card not valid for Medicare)	$250 to $450/month
Uninsured, paying cash	$1,069/month, or $519/month with savings card (state-dependent)	$1,060/month, or $510/month with savings card (state-dependent)	$250 to $450/month

For most patients without insurance coverage, compounded tirzepatide is the lowest-cost option by a factor of two to four.

The decision tree: which version you should ask for

Start here: Do you have type 2 diabetes (A1C ≥6.5% or previous diabetes diagnosis)?

Yes → Ask your provider for Monjaro.

• Insurance is more likely to cover it
• You will benefit from both glucose control and weight loss
• If your plan requires step therapy, complete it (usually metformin for 90 days)
• If denied, appeal with documentation of A1C and prior medication trials

No → Do you have commercial insurance (not Medicare/Medicaid)?

Yes → Check your plan's formulary for Zepbound.

• Call the number on your insurance card and ask: "Does my plan cover Zepbound for obesity? What is the prior authorization process?"
• If covered: Ask your provider for Zepbound and complete prior authorization requirements (usually BMI documentation, 6-month weight management program records, comorbidity documentation)
• If not covered: Consider compounded tirzepatide or cash-pay Zepbound with savings card

No (you have Medicare or Medicaid) → Compounded tirzepatide is likely your only affordable option.

• Medicare Part D excludes weight-loss drugs by statute
• Medicaid coverage for GLP-1s varies by state; check your state's preferred drug list
• Manufacturer savings cards are not valid for government insurance programs
• Out-of-pocket brand-name cost ($1,000+/month) is prohibitive for most patients

Special case: You have obesity AND prediabetes (A1C 5.7% to 6.4%).

Talk with your provider about whether Monjaro is appropriate. Some insurance plans will cover Monjaro for prediabetes prevention, especially if you have other risk factors (family history, previous gestational diabetes, PCOS). This is off-label but clinically reasonable. Your provider will need to document medical necessity.

Special case: You are paying out of pocket regardless of insurance status.

Compare:

• Zepbound with savings card: $510/month (if eligible)
• Compounded tirzepatide: $250 to $450/month
• Monjaro with savings card: $519/month (if eligible)

Compounded tirzepatide offers the best cost-to-benefit ratio for cash-pay patients. The trade-off is the lack of FDA approval and the need to self-inject from a vial rather than using a prefilled pen.

Diagram suggestion: Flowchart starting with "Do you have type 2 diabetes?" branching to insurance type, then to coverage status, with final recommendation (Monjaro / Zepbound / Compounded) at each endpoint. Use decision-tree visual format with yes/no branches.

Side effect profiles: do they differ?

No. The side effect profile is determined by the active ingredient (tirzepatide) and dose, not by the brand name on the package.

The most common side effects across both SURPASS and SURMOUNT trials:

Side effect	Incidence (any tirzepatide dose)	Incidence (placebo)
Nausea	20% to 33%	8% to 10%
Diarrhea	15% to 23%	7% to 9%
Vomiting	8% to 12%	2% to 3%
Constipation	6% to 9%	4% to 5%
Abdominal pain	7% to 10%	4% to 5%
Decreased appetite	5% to 8%	1% to 2%
Injection site reactions	3% to 5%	1% to 2%
Fatigue	4% to 6%	2% to 3%
Dyspepsia	6% to 9%	3% to 4%

Serious adverse events:

• Pancreatitis: 0.2% across trials (vs 0.1% placebo)
• Gallbladder disease (cholecystitis, cholelithiasis): 1.5% to 2.5% (vs 0.6% placebo), associated with rapid weight loss
• Hypoglycemia (glucose <54 mg/dL): 0.6% when used without insulin or sulfonylurea; 10% to 15% when combined with insulin
• Acute kidney injury: Rare, typically in setting of severe dehydration from vomiting/diarrhea
• Diabetic retinopathy complications: Signal seen in SURPASS-4 (3.0% vs 1.8% placebo), primarily in patients with pre-existing retinopathy and rapid A1C reduction

The FDA-mandated boxed warning is identical for both products: risk of thyroid C-cell tumors (seen in rodent studies, not confirmed in humans; contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2).

Patients switching from Monjaro to Zepbound (or vice versa) at the same dose should expect the same side effect experience. The switch is a change in brand name and billing code, not a change in medication.

FormBlends clinical pattern: what we see in compounded tirzepatide transitions

Across the patient population using compounded tirzepatide through FormBlends, the most common reason for choosing compounded over brand-name is insurance denial for Zepbound in patients without diabetes. The second most common reason is cost, even among patients with partial insurance coverage.

The pattern we see most often: a patient starts on brand-name Monjaro or Zepbound, reaches a maintenance dose (typically 7.5 mg to 12.5 mg), achieves stable weight loss, and then switches to compounded tirzepatide to reduce long-term cost. The transition is straightforward because the dose and schedule remain the same. The primary adjustment is learning to draw the medication from a vial using an insulin syringe instead of using a prefilled pen.

A smaller subset of patients starts on compounded tirzepatide from the beginning, typically because they researched costs before seeing a provider and knew insurance would not cover brand-name medication for their indication.

Discontinuation rates for GI side effects are comparable between brand-name and compounded tirzepatide in our patient population (approximately 8% to 10% discontinue during titration due to nausea or vomiting). This matches the published trial data and suggests that formulation differences (if any) do not meaningfully affect tolerability.

The most common question we receive from patients considering a switch from Monjaro or Zepbound to compounded tirzepatide is whether efficacy will change. The answer, based on patient-reported weight-loss trajectories, is no. Patients who switch at a stable dose continue to lose weight at the same rate or maintain their weight loss, depending on where they are in the treatment timeline.

FAQ

Are Monjaro and Zepbound the same drug? Yes. Both contain tirzepatide as the active ingredient, manufactured by Eli Lilly at identical doses. The difference is regulatory: Monjaro is FDA-approved for type 2 diabetes, Zepbound for chronic weight management. The formulation, delivery device, and mechanism of action are the same.

Can I use Monjaro for weight loss if I don't have diabetes? Legally, yes. A provider can prescribe Monjaro off-label for weight management. Practically, most insurance companies will deny coverage for Monjaro if you do not have a diabetes diagnosis, especially after Zepbound's approval. You would pay out of pocket or use a manufacturer savings card if eligible.

Can I use Zepbound if I have diabetes? Yes, but insurance coverage becomes complicated. If you have both diabetes and obesity, most payers will cover Monjaro (the diabetes-indicated version) and deny Zepbound. The clinical effect is the same, so using Monjaro is appropriate. Zepbound is typically reserved for patients with obesity who do not have diabetes.

Why did Eli Lilly create two separate brands for the same drug? Regulatory strategy and market positioning. Filing separate FDA applications allowed faster approval for diabetes patients and created separate reimbursement pathways for diabetes vs obesity indications. It also allowed different pricing and marketing strategies for each patient population.

Which is more effective for weight loss, Monjaro or Zepbound? Neither. They contain the same active ingredient at the same doses. Weight-loss efficacy is determined by tirzepatide dose, not brand name. A patient on 10 mg Monjaro will lose the same amount of weight as a patient on 10 mg Zepbound, assuming similar adherence and baseline characteristics.

Does Monjaro lower blood sugar better than Zepbound? No. The glucose-lowering effect is identical at the same dose because the medication is identical. Zepbound was not studied primarily for diabetes, but the SURMOUNT-2 trial (which enrolled patients with obesity and diabetes) showed A1C reductions of 2.0% to 2.3%, matching the SURPASS trial results for Monjaro.

Can I switch from Monjaro to Zepbound or vice versa? Yes. If you are switching at the same dose (e.g., 10 mg Monjaro to 10 mg Zepbound), you can make the switch immediately without retitration. The medication in your system is the same. The switch is administrative (new prescription, new NDC billed to insurance), not clinical.

Will my insurance cover both Monjaro and Zepbound? Unlikely. Most insurance plans cover one or the other based on your diagnosis. If you have diabetes, they cover Monjaro. If you have obesity without diabetes, some plans cover Zepbound. Very few plans cover both for the same patient because the drugs are therapeutically equivalent.

Is compounded tirzepatide as effective as Monjaro or Zepbound? Compounded tirzepatide contains the same active ingredient and should produce the same clinical effects at the same dose. However, compounded medications are not FDA-approved and have not undergone the same testing for consistency and stability as brand-name products. Patient-reported outcomes suggest comparable efficacy, but head-to-head trial data does not exist.

How much does Monjaro cost compared to Zepbound? List prices are nearly identical: approximately $1,060 to $1,070 per month for either brand. With insurance, your out-of-pocket cost depends on your plan's coverage and copay structure. With a manufacturer savings card, both can cost as little as $25 per month for eligible patients. Without insurance or savings card eligibility, both cost $1,000+ per month.

Can I use a Monjaro savings card for Zepbound? No. The savings cards are brand-specific. The Monjaro Savings Card applies only to Monjaro prescriptions. The Zepbound Savings Card applies only to Zepbound prescriptions. They have similar eligibility criteria and discount amounts but are separate programs.

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies will be required to stop producing compounded tirzepatide within a short period (typically 60 days after FDA notification). Patients using compounded tirzepatide would need to switch to brand-name Monjaro or Zepbound or discontinue treatment. As of April 2026, tirzepatide remains on the shortage list with no announced resolution date.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
5. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. Lancet Diabetes Endocrinol. 2022.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
8. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2024.
9. Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. 2024.
10. FDA. Drug Shortages Database. Tirzepatide injection. Updated April 2026.
11. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2023.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. UnitedHealthcare. Clinical Policy: GLP-1 Receptor Agonists. Updated January 2024.
14. Anthem. Pharmacy Clinical Policy: Tirzepatide. Updated February 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Monjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.